WHAT IS CLAIMED IS:

1. A pharmaceutical tablet comprising:

a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, selected from: about 0.5635mg, about 1.127mg, and about 2.254mg;

wherein,

b) the tablet contains from about 25% to about 89% by weight of one or more excipients, where the excipients are substantially free of water; and

c) the amount of unsolvated drug does not exceed about 20%.

2. A pharmaceutical tablet according to claim 1 wherein the amount of unsolvated drug does not exceed about 15%.

3. A pharmaceutical tablet according to claim 1 wherein the amount of unsolvated drug does not exceed about 10%.

4. A pharmaceutical tablet according to claim 1 wherein the amount of unsolvated drug does not exceed about 5%.

5. A pharmaceutical tablet according to claim 1 wherein the amount of unsolvated drug does not exceed about 2%.

6. A pharmaceutical tablet according to any one of the preceding claims wherein the drug particles are micronized.

7. A pharmaceutical tablet according to any one of the preceding claims wherein at least 50% of the drug particles have a particle size of 30 micron or less.

8. A pharmaceutical tablet according to any one of the preceding claims wherein at least 50% of the drug particles have a particle size of 5 micron or less.

9. A pharmaceutical tablet according to any one of the preceding claims wherein the tablet contains from about 25% to about 89% by weight of one or more excipients selected from: microcrystalline cellulose, powdered cellulose, pregelatinized starch, starch, lactose, Di-calcium phosphate, lactitol, mannitol, sorbitol and maltodextrin, where the excipients are substantially free of water.

10. A pharmaceutical tablet according to any one of the preceding claims wherein the tablet is produced on a scale suitable to prepare at least about 50,000 tablets.

11. A pharmaceutical tablet according to any one of the preceding claims wherein the tablet is film coated.

12. A pharmaceutical tablet according to any one of the preceding claims wherein the tablet is film coated and wherein the film coating contains a colorant.

13. A pharmaceutical tablet according to any one of the preceding claims wherein the tablet is film coated and wherein the film coating contains a colorant that contains iron oxide.

14. A pharmaceutical tablet according to any one of the preceding claims for use in treating cancer in a human in need thereof.

15. A process for preparing pharmaceutical tablets containing an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-

3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, in an amount selected from: about 0.5635mg, about 1.127mg, and about 2.254mg, which process comprises the steps of;

admixing:

N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate,

one or more excipients, where the excipients are substantially free of water, and

further excipients,

to form a mixture; and

compressing the mixture into tablets;

provided:

each tablet contains N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxidein solvate in an amount selected from: about 0.5635mg, about 1.127mg, and about 2.254mg;

each tablet contains from about 25% to about 89% by weight of one or more excipients, where the excipients are substantially free of water; and

the amount of unsolvated drug does not exceed about 20%.

16. Use of a pharmaceutical tablet according to any one of claims 1-13 in the manufacture of a medicament for treating cancer in a human in need thereof.

Claims

1. A pharmaceutical tablet comprising:

a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein,

b) the tablet contains from about 25% to about 89% by weight of one or more excipients, where the excipients are substantially free of water;

and c) the amount of unsolvated drug does not exceed about 20%.

2. The pharmaceutical tablet, according to claim 1, comprising:

a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, selected from: about 0.5635 mg; about 1.127 mg, and about 2.254 mg; wherein,

b) the drug particles are micronized;

c) the tablet contains from about 25% to about 89% by weight of one or more excipients, where the excipients are substantially free of water; and

d) the amount of unsolvated drug does not exceed about 20%.

3. The pharmaceutical tablet, according to claim 1, comprising:

a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein,

b) the drug particles are micronized;

c) the tablet contains from about 25% to about 89% by weight of one or more excipients selected from: microcrystalline cellulose, powdered cellulose, pregelatinized starch, starch, lactose, Di-calcium phosphate, lactitol, mannitol, sorbitol and maltodextrin, where the excipients are substantially free of water; and

d) the amount of unsolvated drug does not exceed about 20%.

4. The pharmaceutical tablet, according to claim 1, comprising:

a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein,

b) the drug particles are micronized;

c) the tablet contains from about 25% to about 89% by weight of one or more excipients selected from: microcrystalline cellulose, powdered cellulose, pregelatinized starch, starch, lactose, Di-calcium phosphate, lactitol, mannitol, sorbitol and maltodextrin, where the excipients are substantially free of water; and

d) the amount of unsolvated drug does not exceed about 20%;

e) the tablet is film coated.

5. The pharmaceutical tablet, according to claim 1, comprising:

a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein,

b) the drug particles are micronized;

c) the tablet is produced on a scale suitable to prepare at least about 50,000 tablets;

d) the tablet contains from about 25% to about 89% by weight of one or more excipients selected from: microcrystalline cellulose, powdered cellulose, pregelatinized starch, starch, lactose, Di-calcium phosphate, lactitol, mannitol, sorbitol and maltodextrin, where the excipients are substantially free of water;

e) the amount of unsolvated drug does not exceed about 20%; and

f) the tablet is film coated.

6. The pharmaceutical tablet, according to claim 1, comprising:

a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein,

b) the drug particles are micronized;

c) the tablet is produced on a scale suitable to prepare at least about 50,000 tablets;

d) the tablet contains from about 25% to about 89% by weight of one or more excipients selected from: microcrystalline cellulose, powdered cellulose, pregelatinized starch, starch, lactose, Di-calcium phosphate, lactitol, mannitol, sorbitol and maltodextrin, where the excipients are substantially free of water;

e) the amount of unsolvated drug does not exceed about 20%; and

f) the tablet is film coated and wherein the film coating contains a colorant.

7. The pharmaceutical tablet, according to claim 1, comprising:

a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein,

b) the drug particles are micronized;

c) the tablet is produced on a scale suitable to prepare at least about 50,000 tablets;

d) the tablet contains from about 25% to about 89% by weight of one or more excipients selected from: microcrystalline cellulose, powdered cellulose, pregelatinized starch, starch, lactose, Di-calcium phosphate, lactitol, mannitol, sorbitol and maltodextrin, where the excipients are substantially free of water;

e) the amount of unsolvated drug does not exceed about 20%; and

f) the tablet is film coated and wherein the film coating contains a colorant that contains iron oxide.

8. The pharmaceutical tablet comprising:

a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein,

b) at least 50% of the drug particles have a particle size of 30 micron or less;

c) the tablet contains from about 25% to about 89% by weight of one or more excipients, where the excipients are substantially free of water; and

d) the amount of unsolvated drug does not exceed about 20%.

9. The pharmaceutical tablet, according to claim 8, comprising:

a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein,

b) at least 50% of the drug particles have a particle size of 30 micron or less;

c) the tablet contains from about 25% to about 89% by weight of one or more excipients selected from: microcrystalline cellulose, powdered cellulose, pregelatinized starch, starch, lactose, Di-calcium phosphate, lactitol, mannitol, sorbitol and maltodextrin, where the excipients are substantially free of water; and

d) the amount of unsolvated drug does not exceed about 20%.

10. The pharmaceutical tablet, according to claim 8, comprising:

a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein,

b) at least 50% of the drug particles have a particle size of 30 micron or less;

c) the tablet contains from about 25% to about 89% by weight of one or more excipients selected from: microcrystalline cellulose, powdered cellulose, pregelatinized starch, starch, lactose, Di-calcium phosphate, lactitol, mannitol, sorbitol and maltodextrin, where the excipients are substantially free of water; and

d) the amount of unsolvated drug does not exceed about 20%; and

e) the tablet is film coated.

11. The pharmaceutical tablet, according to claim **8**, comprising:

a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein,

b) at least 50% of the drug particles have a particle size of 30 micron or less;

c) the tablet is produced on a scale suitable to prepare at least about 50,000 tablets;

d) the tablet contains from about 25% to about 89% by weight of one or more excipients selected from: microcrystalline cellulose, powdered cellulose, pregelatinized starch, starch, lactose, Di-calcium phosphate, lactitol, mannitol, sorbitol and maltodextrin, where the excipients are substantially free of water; and

d) the amount of unsolvated drug does not exceed about 20%; and

e) the tablet is film coated.

12. The pharmaceutical tablet, according to claim **8**, comprising:

a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein,

b) at least 50% of the drug particles have a particle size of 30 micron or less;

c) the tablet is produced on a scale suitable to prepare at least about 50,000 tablets;

d) the tablet contains from about 25% to about 89% by weight of one or more excipients selected from: microcrystalline cellulose, powdered cellulose, pregelatinized starch, starch, lactose, Di-calcium phosphate, lactitol, mannitol, sorbitol and maltodextrin, where the excipients are substantially free of water;

e) the amount of unsolvated drug does not exceed about 20%; and

f) the tablet is film coated and wherein the film coating contains a colorant.

13. The pharmaceutical tablet, according to claim **8**, comprising:

a) an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg; wherein,

b) at least 50% of the drug particles have a particle size of 30 micron or less;

c) the tablet contains from about 25% to about 89% by weight of one or more excipients, where the excipients are substantially free of water; and

d) the amount of unsolvated drug does not exceed about 20%; and

e) the tablet is film coated and wherein the film coating contains a colorant that contains iron oxide.

14. The pharmaceutical tablet according to claim **6** wherein:

the tablet contains from about 25% to about 89% by weight of one or more excipients selected from: microcrystalline cellulose and mannitol.

15. The pharmaceutical tablet according to claim **9** wherein:

the tablet contains from about 25% to about 89% by weight of one or more excipients selected from: microcrystalline cellulose and mannitol.

16. A process for preparing pharmaceutical tablets containing an amount of a drug, which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl] phenyl}acetamide dimethyl sulfoxide solvate, selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg, which process comprises the steps of;

admixing: N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl] phenyl}acetamide dimethyl sulfoxide solvate, one or more excipients, where the excipients are substantially free of water, and further excipients, to form a mixture; and compressing the mixture into tablets; provided: each tablet contains N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl] phenyl}acetamide dimethyl sulfoxide solvate in an amount selected from: about 0.5635 mg, about 1.127 mg, and about 2.254 mg;

each tablet contains from about 25% to about 89% by weight of one or more excipients, where the excipients are substantially free of water; and

the amount of unsolvated drug does not exceed about 20%.